These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35899825)

  • 1. Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma.
    Riehl L; Mulaw M; Kneer K; Beer M; Beer A; Barth TF; Benes V; Schulte J; Fischer M; Debatin KM; Beltinger C
    Cancer Rep (Hoboken); 2023 Jan; 6(1):e1687. PubMed ID: 35899825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse.
    Riehl LM; Schulte JH; Mulaw MA; Dahlhaus M; Fischer M; Schramm A; Eggert A; Debatin KM; Beltinger C
    Oncotarget; 2016 Feb; 7(6):6620-5. PubMed ID: 26735174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
    Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
    Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma.
    Lodrini M; Graef J; Thole-Kliesch TM; Astrahantseff K; Sprüssel A; Grimaldi M; Peitz C; Linke RB; Hollander JF; Lankes E; Künkele A; Oevermann L; Schwabe G; Fuchs J; Szymansky A; Schulte JH; Hundsdörfer P; Eckert C; Amthauer H; Eggert A; Deubzer HE
    Clin Cancer Res; 2022 May; 28(9):1809-1820. PubMed ID: 35247920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer.
    Chamberlin MD; Wells JD; Shee K; Bean JR; Marotti JD; Wells WA; Trask HW; Kolling FW; Bhatt A; Kaufman PA; Schwartz GN; Gemery JM; McNulty NJ; Tsapakos MJ; Barth RJ; Arrick BA; Gui J; Miller TW
    Breast Cancer Res Treat; 2020 Aug; 182(3):665-677. PubMed ID: 32562118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.
    Padovan-Merhar OM; Raman P; Ostrovnaya I; Kalletla K; Rubnitz KR; Sanford EM; Ali SM; Miller VA; Mossé YP; Granger MP; Weiss B; Maris JM; Modak S
    PLoS Genet; 2016 Dec; 12(12):e1006501. PubMed ID: 27997549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted mutation detection in breast cancer using MammaSeq™.
    Smith NG; Gyanchandani R; Shah OS; Gurda GT; Lucas PC; Hartmaier RJ; Brufsky AM; Puhalla S; Bahreini A; Kota K; Wald AI; Nikiforov YE; Nikiforova MN; Oesterreich S; Lee AV
    Breast Cancer Res; 2019 Feb; 21(1):22. PubMed ID: 30736836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma.
    Chicard M; Colmet-Daage L; Clement N; Danzon A; Bohec M; Bernard V; Baulande S; Bellini A; Deveau P; Pierron G; Lapouble E; Janoueix-Lerosey I; Peuchmaur M; Corradini N; Defachelles AS; Valteau-Couanet D; Michon J; Combaret V; Delattre O; Schleiermacher G
    Clin Cancer Res; 2018 Feb; 24(4):939-949. PubMed ID: 29191970
    [No Abstract]   [Full Text] [Related]  

  • 9. High mutation burden of circulating cell-free DNA in early-stage breast cancer patients is associated with a poor relapse-free survival.
    Kujala J; Hartikainen JM; Tengström M; Sironen R; Kosma VM; Mannermaa A
    Cancer Med; 2020 Aug; 9(16):5922-5931. PubMed ID: 32602248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence.
    Ueda M; Iguchi T; Masuda T; Nakahara Y; Hirata H; Uchi R; Niida A; Momose K; Sakimura S; Chiba K; Eguchi H; Ito S; Sugimachi K; Yamasaki M; Suzuki Y; Miyano S; Doki Y; Mori M; Mimori K
    Oncotarget; 2016 Sep; 7(38):62280-62291. PubMed ID: 27556701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-invasive analysis of tumor mutation profiles and druggable mutations by sequencing of cell free DNA of Chinese metastatic breast cancer patients.
    Li S; Wang X; Li Y; Lai H; Liu Y; Jin L
    Thorac Cancer; 2019 Apr; 10(4):807-814. PubMed ID: 30793491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-Specific Mitochondrial DNA Variants Are Rarely Detected in Cell-Free DNA.
    Weerts MJA; Timmermans EC; van de Stolpe A; Vossen RHAM; Anvar SY; Foekens JA; Sleijfer S; Martens JWM
    Neoplasia; 2018 Jul; 20(7):687-696. PubMed ID: 29842994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
    Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
    Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Implications of Circulating Tumor DNA from Ascites and Serial Plasma in Ovarian Cancer.
    Han MR; Lee SH; Park JY; Hong H; Ho JY; Hur SY; Choi YJ
    Cancer Res Treat; 2020 Jul; 52(3):779-788. PubMed ID: 32106643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosomes from Plasma of Neuroblastoma Patients Contain Doublestranded DNA Reflecting the Mutational Status of Parental Tumor Cells.
    Degli Esposti C; Iadarola B; Maestri S; Beltrami C; Lavezzari D; Morini M; De Marco P; Erminio G; Garaventa A; Zara F; Delledonne M; Ognibene M; Pezzolo A
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33915956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of circulating tumor DNA by digital droplet PCR in resectable lung cancer as a predictive tool for recurrence.
    Gassa A; Fassunke J; Schueten S; Kuhlmann L; Scherer M; Qien J; Zhao Y; Michel M; Loeser H; Wolf J; Buettner R; Doerr F; Heldwein M; Hagmeyer L; Frank K; Merkelbach-Bruse S; Quaas A; Bruns C; Hekmat K; Weiss J; Wahlers T; Alakus H
    Lung Cancer; 2021 Jan; 151():91-96. PubMed ID: 33257044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-generation sequencing of the whole mitochondrial genome identifies functionally deleterious mutations in patients with multiple sclerosis.
    Al-Kafaji G; Bakheit HF; AlAli F; Fattah M; Alhajeri S; Alharbi MA; Daif A; Alsabbagh MM; Alwehaidah MS; Bakhiet M
    PLoS One; 2022; 17(2):e0263606. PubMed ID: 35130313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding Clone.
    Abbasi MR; Rifatbegovic F; Brunner C; Mann G; Ziegler A; Pötschger U; Crazzolara R; Ussowicz M; Benesch M; Ebetsberger-Dachs G; Chan GCF; Jones N; Ladenstein R; Ambros IM; Ambros PF
    Clin Cancer Res; 2017 Aug; 23(15):4224-4232. PubMed ID: 28228384
    [No Abstract]   [Full Text] [Related]  

  • 19. Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer.
    Chin YM; Takahashi Y; Chan HT; Otaki M; Fujishima M; Shibayama T; Miki Y; Ueno T; Nakamura Y; Low SK
    Cancer Sci; 2021 Jan; 112(1):454-464. PubMed ID: 33075187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing single-target and multitarget approaches for postoperative circulating tumour DNA detection in stage II-III colorectal cancer patients.
    Henriksen TV; Reinert T; Rasmussen MH; Demuth C; Løve US; Madsen AH; Gotschalck KA; Iversen LH; Andersen CL
    Mol Oncol; 2022 Oct; 16(20):3654-3665. PubMed ID: 35895438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.